Advertisement

Mechanism and consequences of nerve cell death in Parkinson’s disease

  • Etienne C. Hirsch
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 56)

Summary

The etiology of Parkinson’s disease remains unknown, making it difficult to develop therapeutical approaches to stop the progression of the disease. The best known treatment to date is based on the use of L-DOPA or dopaminergic agonists. These are merely substitutive therapies and have limitations because of their side effects. Thus, the development of new therapeutical strategies will require a far better knowledge of the mechanism and the consequences of nerve cell death in Parkinson’s disease.

Parkinson’s disease is characterized by a selective vulnerability of sub-populations of dopaminergic neurons in the mesencephalon. The fact that the neurons which degenerate in Parkinson’s disease are already sensitive to oxidative stress in control subjects and the reported increased production of oxygen free radicals in Parkinson’s disease suggest that oxidative stress may be involved in the mechanism of nerve cell death. Furthermore, oxygen free radicals are also involved in an oxygen-dependent pro-apoptotic pathway stimulated by the inflammatory reaction observed in Parkinson’s disease. These data suggest that anti-oxidant or anti-inflammatory treatments may slow down the progression of the disease.

On the other hand, new substitutive therapies may be developed by trying to restore the activity of the neurons located downstream from the nigrostriatal pathway. Indeed, the nigrostriatal denervation induces a hyper- activity of the output structures of the basal ganglia (internal segment of the globus pallidus and substantia nigra pars reticulata), as demonstrated in various animal models of the disease. These changes in the activity of the output structures of the basal ganglia seem to be directly induced by the hyperactivity of the glutamatergic afferent fibers from the subthalamic nucleus. The fact that L-DOPA treatment or a reduction in the activity of the subthalamic nucleus alleviate the symptoms of the disease and restore the activity of the output structures of the basal ganglia in parkinsonism suggests that these structures play a key role in the pathophysiology of the disease and could represent a potential therapeutic target.

Keywords

Basal Ganglion Substantia Nigra Dopaminergic Neuron Nerve Cell Death Cytochrome Oxidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alam ZI, Daniel SE, Lees AJ, Marsden CD, Jenner P, Halliwell B (1997a) A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J Neurochem 69: 1326–1329PubMedCrossRefGoogle Scholar
  2. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997b) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196–1203PubMedCrossRefGoogle Scholar
  3. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366–375PubMedCrossRefGoogle Scholar
  4. Aziz TZ, Peggs D, Sambrook MA, Crossman AR (1991) Lesions of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 4: 288–292CrossRefGoogle Scholar
  5. Aziz TZ, Peggs D, Agarwal E, Sambrook MA, Crossman AR (1992) Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-exposed primate. Br J Neurosurg 6: 575–582PubMedCrossRefGoogle Scholar
  6. Barbeau A, Roy M (1985) Identification of environemental related foci of Parkinson’s disease in the Province of Quebec. Ann Neurol 18: 138Google Scholar
  7. Beal MF (1996) Mitochondria, free radicals and neurodegeneration. Curr Opin Neurobiol 6: 661–666PubMedCrossRefGoogle Scholar
  8. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5: 382–389PubMedCrossRefGoogle Scholar
  9. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436–1438PubMedCrossRefGoogle Scholar
  10. Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72: 507–520PubMedGoogle Scholar
  11. Bernard V, Gardiol A, Faucheux B, Bloch B, Agid Y, Hirsch EC (1996) Expression of glutamate receptors in the human and rat basal ganglia: effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson’s disease and rat with 6-OHDA lesion. J Comp Neurol 368: 553–568PubMedCrossRefGoogle Scholar
  12. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunocy-tochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172: 151–154PubMedCrossRefGoogle Scholar
  13. Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR (1991) Alleviation of parkinsonism by antagonism of excitatory aminoacid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 6: 133–138PubMedCrossRefGoogle Scholar
  14. Brugg B, Michel PP, Agid Y, Ruberg M (1996) Ceramide induces apoptosis in cultured mesencephalic neurons. J Neurochem 66: 733–739PubMedCrossRefGoogle Scholar
  15. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immuno 149: 2736–2741Google Scholar
  16. Chesselet MF, Mercugliano M, Soghomonian JJ, Salin P, Qin Y, Gonzales C (1993) Regulation of glutamic acid decarboxylase gene expression in efferent neurons of the basal ganglia. Prog Brain Res 99: 143–154PubMedCrossRefGoogle Scholar
  17. Crossman AR (1989) Neural mechanisms in disorders of movement. Comp Biochem Physiol 93: 141–149CrossRefGoogle Scholar
  18. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52: 1–6PubMedCrossRefGoogle Scholar
  19. Damier P, Hirsch EC, Agid Y, Graybiel AM (1997) Temporospatial progression of the loss in dopaminergic neurons in the substantia nigra in Parkinson’s disease. Mov Disord 12 [Suppl 1]: 274Google Scholar
  20. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 8: 6368–6371CrossRefGoogle Scholar
  21. Dawson VL, Brahmbhatt HP, Mong JA, Dawson TM (1994) Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 33: 1425–1430PubMedCrossRefGoogle Scholar
  22. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13: 281–285CrossRefGoogle Scholar
  23. Demerlé-Palladry C, Lonchampt MO, Chabrier PE, Braquet P (1993) Nitric oxide synthase induction in glial cells: effect on neuronal survival. Life Sci 52: 1883–1890CrossRefGoogle Scholar
  24. Good PF, Olanow CW, Perl DP (1992) Neuromelanin-containing neurons of the substan-tia nigra accumulate iron and aluminum in Parkinson’s disease: a LAMMA study. Brain Res 593: 343–346PubMedCrossRefGoogle Scholar
  25. Graham DG (1979) On the origin and significance of neuromelanin. Arch Pathol Lab Med 103: 359–362PubMedGoogle Scholar
  26. Graham WC, Robertson RG, Sambrook MA, Crossman AR (1990) Injection of excitatory amino acid antagonists into the medial pallidal segment of a (MPTP) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated primate reverses motor symptoms of parkinsonism. Life Sci 47: PL-91–7CrossRefGoogle Scholar
  27. Guridi J, Herrero MT, Luquin MR, Guillen J, Ruberg M, Laguna J, Vila M, Javoy-Agid F, Agid Y, Hirsch EC, Obeso JA (1996) Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 119: 1717–1727Google Scholar
  28. Hannun YA, Obeid LM (1995) Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 20: 73–77PubMedCrossRefGoogle Scholar
  29. Herrero MT, Levy R, Ruberg M, Luquin MR, Villares J, Guillen J, Faucheux B, Javoy-Agid F, Guridi J, Agid Y, Obeso JA, Hirsch EC (1996) Consequence of nigrostriatal denervation and L-DOPA therapy on the expression of glutamic acid decarboxylase (GAD) messenger RNA in the pallidum. Neurology 47: 219–224PubMedCrossRefGoogle Scholar
  30. Hevner RF, Wong-Riley MTT (1991) Neuronal expression of nuclear and mitochondrial genes for cytochrome oxidase (CO) subunits analyzed by in situ hybridization: comparison with CO activity and protein. J Neurosci 11: 1942–1958PubMedGoogle Scholar
  31. Hirsch EC (1993) Does oxidative stress participate in nerve cell death in Parkinson’s disease? Eur Neurol 33: 52–59PubMedCrossRefGoogle Scholar
  32. Hirsch EC, Graybiel AM, Agid Y (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334: 345–348PubMedCrossRefGoogle Scholar
  33. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson’s disease. An X-ray microanalysis. J Neurochem 56: 446–451PubMedCrossRefGoogle Scholar
  34. Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and the inflammatory reaction in Parkinson’s disease: a role in neurodegeneration? Ann Neurol 44 [Suppl]: S115–S120PubMedGoogle Scholar
  35. Hopkins SJ, Rothwell NJ (1995) Cytokines and the nervous system I: expression and recognition. Trends Neurosci 18: 83–88PubMedCrossRefGoogle Scholar
  36. Hornykiewicz O (1963) Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia Nigra des normalen und parkinsonkranken Menschen. Wien Klin Wochenschr 75: 309–321PubMedGoogle Scholar
  37. Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72: 355–363PubMedCrossRefGoogle Scholar
  38. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997a) Nuclear translocation of NF-kB is increased in dopaminergic neurons of patients with Parkinson’s disease. Proc Natl Acad Sci USA 94: 7531–7536PubMedCrossRefGoogle Scholar
  39. Hunot S, Betard C, Faucheux B, Agid Y, Hirsch EC (1997b) Immunohistochemical analysis of interferon-γ and interleukin-lβ in the substantia nigra of Parkinsonian patients. Mov Disord 12 [Suppl 1]: 20Google Scholar
  40. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Schachar D, Youdim MBH (1992) Iron-melanin complex in substantia nigra of parkinsonian brain: an X-ray microanalysis. J Neurochem 59: 1168–1171PubMedCrossRefGoogle Scholar
  41. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann Neurol 28: 539–546PubMedCrossRefGoogle Scholar
  42. Kolesnick R, Golde DW (1994) The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77: 325–328PubMedCrossRefGoogle Scholar
  43. Limousin P, Pollak P, Benazzouz A, Hoffman D, Le Bras J-F, Broussolle E, et al (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345: 91–95PubMedCrossRefGoogle Scholar
  44. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y (1994) Levodopa-induced dyskinesias in Parkinson’s disease phenomenology and pathophysiology. Mov Disord 9: 2–12PubMedCrossRefGoogle Scholar
  45. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs DE, Sambrook MA, Crossman AR (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32: 213–226PubMedCrossRefGoogle Scholar
  46. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Susuki K, Sato T, Oya H, Ozawa Y, Kagawa Y (1993) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163: 1450–1455CrossRefGoogle Scholar
  47. Owen AD, Schapira AH, Jenner P, Marsden CD (1996) Oxidative stress and Parkinson’s disease. Ann N Y Acad Sci 786: 217–223PubMedCrossRefGoogle Scholar
  48. Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305–310PubMedCrossRefGoogle Scholar
  49. Polymeropoulos MH, Lavedant C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276: 2045–2047PubMedCrossRefGoogle Scholar
  50. Porter RHP, Greene JG, Higgins Jr DS, Greenamyre JT (1994) Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J Neurosci 14: 7192–7199PubMedGoogle Scholar
  51. Saggu H, Cooksey J, Dexter D, Welles FR, Lees AJ, Jenner P, Marsden CD (1989) A selective increase in particulate Superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692–697PubMedCrossRefGoogle Scholar
  52. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54: 823–827PubMedCrossRefGoogle Scholar
  53. Soghomonian JJ, Chesselet MF (1992) Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat. Synapse 11: 124–133PubMedCrossRefGoogle Scholar
  54. Starr MS (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson’s disease. Synapse 19: 264–293PubMedCrossRefGoogle Scholar
  55. Vila M, Herrero MT, Levy R, Faucheux B, Ruberg M, Guillen J, Luquin MR, Guridi J, Javoy-Agid F, Agid Y, Obeso JA, Hirsch EC (1996a) Consequence of nigrostiatal denervation on the GABAergic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology 46: 802–809PubMedCrossRefGoogle Scholar
  56. Vila M, Levy R, Herrero MT, Faucheux B, Obeso JA, Agid Y, Hirsch EC (1996b) Metabolic activity of the basal ganglia in parkinsonian syndromes in human and nonhuman primates: a cytochrome oxidase histochemistry study. Neuroscience 71: 903–912PubMedCrossRefGoogle Scholar
  57. Vila M, Levy R, Herrero MT, Ruberg M, Faucheux B, Obeso JA, Agid Y, Hirsch EC (1997) Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J Neurosci 17: 765–773PubMedGoogle Scholar
  58. Wichmann T, Bergman H, DeLong MR (1994) The primate subthalamic nucleus. I. Functional properties in intact animals. J Neurophysiol 72: 494–506PubMedGoogle Scholar
  59. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB (1993) Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 90: 9813–9817PubMedCrossRefGoogle Scholar
  60. Wong-Riley MTT (1989) Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci 12: 94–101PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • Etienne C. Hirsch
    • 1
  1. 1.Recherche CNRSHôpital de la SâlpêtrièreParis Cedex 13France

Personalised recommendations